Belite Bio, Inc (BLTE) Insider Trading
Over the last 3 months, BLTE insiders made 0 open-market buys and 16 sales, a net sale of -$3.0M (SEC Form 4). Over the last 6 months, 28 institutions increased and 15 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
16
Net (3m)
-$3.0M
Insider trades by month Buys Sells
Apr
May
Jun
Aug
Context3-month price +5.4%Institutions reducing (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Lin Yu-Hsindirector, officer: Chief Executive Officer | Sell | 223 | $180.57 |
| Aug 14, 2026 | Chuang Hao-Yuandirector, officer: Chief Financial Officer | Sell | 144 | $180.00 |
| Aug 14, 2026 | Chuang Hao-Yuandirector, officer: Chief Financial Officer | Sell | 223 | $180.57 |
| Aug 14, 2026 | Lin Yu-Hsindirector, officer: Chief Executive Officer | Sell | 142 | $180.00 |
| Jun 22, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 1,199 | $146.24 |
| Jun 22, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 4,861 | $145.43 |
| Jun 22, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 3,748 | $144.66 |
| Jun 22, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 96 | $143.90 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 2,054 | $137.61 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 1,035 | $145.02 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 1,897 | $143.55 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 450 | $142.20 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 100 | $141.83 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 540 | $140.58 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 3,140 | $139.57 |
| Jun 17, 2026 | Scholl Hendrik Peterofficer: Chief Medical Officer | Sell | 784 | $138.18 |
| May 8, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 428 | $153.56 |
| May 8, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 9 | $155.25 |
| May 8, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 3 | $154.61 |
| May 8, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 226 | $152.45 |
| May 7, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 100 | $155.97 |
| May 7, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 128 | $153.42 |
| May 7, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 424 | $152.67 |
| May 7, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 240 | $154.41 |
| May 7, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 8 | $151.57 |
| May 6, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 120 | $153.92 |
| May 6, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 68 | $158.11 |
| May 6, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 155 | $157.29 |
| May 6, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 121 | $156.53 |
| May 6, 2026 | MATA NATHAN L.officer: Chief Scientific Officer | Sell | 173 | $155.48 |
Source: BLTE SEC Form 4 filings, latest Aug 14, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their BLTE positions over the last 6 months (SEC Form 13F).
Increased
28
New positions
28
Reduced
15
Sold out
77
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| DARWIN GLOBAL MANAGEMENT, LTD. | Increased | 3.1M | May 15, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | New Position | 1.1M | May 15, 2026 |
| UBS GROUP AG | Increased | 768K | May 5, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 715K | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 570K | May 15, 2026 |
| HOLOCENE ADVISORS, LP | Increased | 494K | May 15, 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | Reduced | 358K | May 15, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Increased | 304K | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | New Position | 282K | May 15, 2026 |
| MORGAN STANLEY | Increased | 201K | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Reduced | 152K | May 29, 2026 |
| PATIENT SQUARE CAPITAL LP | New Position | 117K | May 15, 2026 |
| DUQUESNE FAMILY OFFICE LLC | New Position | 106K | May 15, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 106K | May 15, 2026 |
| BIOIMPACT CAPITAL LLC | Increased | 88K | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.